- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06575270
Hudpigment/pulsoksymeter ved medfødt hjertesykdom (CHD)
Pulsoksymetrinøyaktighet og hudpigmentering ved medfødt hjertesykdom: en prospektiv observasjonsstudie
Recent retrospective studies have demonstrated differences between pulse oximeter values (SpO2) and measured arterial oxygen saturation (SaO2) in patients identifying as Black or Hispanic. These retrospective studies have limitations because self-reported race is likely not an accurate metric for level of skin pigmentation and the retrospective nature of these studies may impact the accuracy of simultaneous measures of arterial oxygen saturation and pulse oximeter values. The few prospective studies that have evaluated this issue have utilized color-matching techniques to quantify skin pigmentation, and fewer studies have directly measured skin pigmentation in relation it to pulse oximeter accuracy. The aim of this study is to prospectively measure pulse oximeter accuracy in relation to measured levels of skin pigmentation in the congenital heart disease population.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This is a prospective observational study aiming to evaluate the relationship between pulse oximeter accuracy to the measured level of skin pigmentation in pediatric patients with congenital heart disease (CHD). These patients live with varying levels of hypoxemia, making them an ideal study population to investigate this critical patient safety issue. The study population will be pediatric patients (age <18 years old) with a diagnosis of congenital heart disease presenting for cardiac surgery at the Mount Sinai Hospital. These patient's will undergo surgery as per protocol, as if they were not in a research study, but will have their skin pigment measured using a non-invasive device (color spectrophotometer) prior to surgery. As part of the normal surgery protocols, arterial blood gas samples will be completed. The measured oxygen levels (SaO2) on arterial blood gas will be compared to the pulse oximeter value using simultaneous measurements to ensure the measures are concurrent. After cardiopulmonary bypass is initiated for the surgery, the subject's involvement in the study will be completed.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Garrett W. Burnett, M.D.
- Telefonnummer: 212-241-7473
- E-post: garrett.burnett@mountsinai.org
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10029
- Rekruttering
- Mount Sinai Hospital
-
Ta kontakt med:
- Garrett W. Burnett, M.D.
- Telefonnummer: 212-241-7473
- E-post: garrett.burnett@mountsinai.org
-
Hovedetterforsker:
- Garrett W. Burnett
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Pediatric patients with a past medical history of congenital heart disease presenting for cardiac surgery under general anesthesia with anticipated arterial vascular access.
Beskrivelse
Inclusion Criteria:
- Pediatric patients (age less than 18 years old) with a diagnosis of CHD (cyanotic or acyanotic) who are presenting for cardiac surgery under general anesthesia with planned arterial access.
Exclusion Criteria:
- Age greater than 18 years old
- Emergency surgery
- Significant preoperative anemia (hemoglobin <8.0 g/dL)
- Preoperative hemodynamic instability (i.e., >1 vasoactive infusions or mechanical circulatory support)
- The presence of any colored nail polish on the planned site of pulse oximeter placement, planned use of any intravenous dyes intraoperatively, and patient, parent, or guardian refusal.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Pediatric Patients with Congenital Heart Disease
No intervention will take place in this observational study. All patients will have their skin pigment measured using a color spectrophotometer and color matching techniques (Fitzpatrick Scale, Monk Skin Tone Scale). Two pulse oximeters will be utilized and pulse oximeter readings will be compared to simultaneous measured arterial saturations. After cardiopulmonary bypass is initiated for the surgery, the subject's involvement in the study will be completed. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Level of Skin Pigmentation
Tidsramme: Day 1 of study participation
|
Pulse oximeter accuracy as it relates to level of skin pigmentation as measured by color spectrophotometry. Pulse oximeter accuracy will be measured using the Accuracy Root Mean Squared (ARMS), mean bias, and proportional bias (Bland-Altman). |
Day 1 of study participation
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Fitzpatrick Skin Tone Scale
Tidsramme: Day 1 of study participation
|
Pulse Oximeter Accuracy in measuring skin pigmentation as measured by Fitzpatrick Skin Tone Scale Pulse oximeter accuracy as it relates to level of skin pigmentation as measured by Fitzpatrick Scale. Scale from I-VI, with higher number indicating darker skin tone |
Day 1 of study participation
|
|
Monk Skin Tone Scale
Tidsramme: Day 1 of study participation
|
Pulse oximeter accuracy as it relates to level of skin pigmentation as measured by Monk Skin Tone Scale. Scale from 1-10, higher numbers indicates darker skin tone. |
Day 1 of study participation
|
|
Number of participants who experience at least one episode of occult hypoxemia
Tidsramme: Day 1 of study participation
|
Incidence of occult hypoxemia, defined as SpO2 ≥92% despite SaO2≤88%, as it relates to measured skin pigment and incidence of occult hypoxemia will be described. Incidence will be measured by assessing the total number of participants who experience at least one episode of occult hypoxemia. |
Day 1 of study participation
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Garrett W. Burnett, M.D., Icahn School of Medicine at Mount Sinai
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Hjertesykdommer
- Hudsykdommer
- Medfødte abnormiteter
- Tegn og symptomer, luftveier
- Kardiovaskulære abnormiteter
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Hud- og bindevevssykdommer
- Tegn og symptomer
- Hjertefeil, medfødt
- Hypoksi
- Pigmentasjonsforstyrrelser
Andre studie-ID-numre
- STUDY-23-00956
- TE00003017 (Annet stipend/finansieringsnummer: Anesthesia Patient Safety Foundation)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All of the individual participant data collected during the trial, after deidentification.
IPD-delingstidsramme
Upon study completion and in accordance with any peer-reviewed journal requirements.
Tilgangskriterier for IPD-deling
Researchers who provide a methodologically sound proposal. To achieve aims in the approved proposal. Proposals should be directed to garrett.burnett@mountsinai.org. To gain access, data requestors will need to sign a data access agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .